Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sai Kottapalli

Vascular Surgery Las Vegas, NV Medical Doctor

NPI 1396278479 CMS profile 11396168

8930 W Sunset Rd Unit 250, Las Vegas, NV 89148

Open in the dashboard

General payments

$53,189

244 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sai Kottapalli of Las Vegas, NV is reported in the CMS Open Payments database as having received $53,189 across 244 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,186 44
2024 General $29,045 104
2023 General $8,510 49
2022 General $4,322 40
2021 General $48 3
2020 General $61 3
2019 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sai Kottapalli
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Sai Kottapalli were reported at $11,186. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Sai Kottapalli Vascular Surgery median Middle half National median
2019 $17 $796 $226–$2,363 $163
2020 $61 $348 $118–$1,110 $114
2021 $48 $471 $158–$1,421 $132
2022 $4,322 $725 $222–$2,183 $149
2023 $8,510 $836 $257–$2,440 $160
2024 $29,045 $909 $252–$2,619 $164
2025 $11,186 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Shockwave Medical, Inc $24,886 34 payments
  2. Penumbra, Inc. $9,759 44 payments
  3. Boston Scientific Corporation $7,340 37 payments
  4. W. L. Gore & Associates, Inc. $6,174 61 payments
  5. Endologix, Inc. $1,031 7 payments
  6. Silk Road Medical, Inc. $920 7 payments
  7. Bolton Medical Inc $695 7 payments
  8. Surmodics, Inc. $480 3 payments
  9. AngioDynamics, Inc. $426 3 payments
  10. LeMaitre Vascular, Inc. $268 7 payments
  11. Other $1,210 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,940 200 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $15,400 7 payments
  3. Consulting Fee $12,313 8 payments
  4. Travel and Lodging $5,474 25 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,600 3 payments
  6. Education $462 1 payment
Products named General payments · program years 2019–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $16,886 24 payments
  2. Indigo System $9,288 39 payments
  3. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $8,001 10 payments
  4. EXCLUDER Conformable AAA Endoprosthesis with Active Control $1,597 12 payments
  5. GORE TAG Thoracic Endoprosthesis $1,434 7 payments
  6. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $1,143 20 payments
  7. ENROUTE Transcarotid Stent $920 7 payments
  8. ENROUTE Transcarotid Neuroprotection System $920 7 payments
  9. GORE TAG Thoracic Branch Endoprosthesis $916 10 payments
  10. GORE TAG Conformable Thoracic Endoprosthesis $705 5 payments
  11. Other $9,127 135 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

180

Median for Vascular Surgery: 122

Drug cost

$18,387

Median for Vascular Surgery: $14,135

Branded share of claims

63.9%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 27 $16,874
Clopidogrel Clopidogrel Bisulfate Brand 88 $623
Gabapentin Generic 37 $580
Cilostazol Generic 15 $174
Atorvastatin Calcium Generic 13 $136

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$280,291

Medicare's payments for the services billed

Medicare patients

404

Average age 73

Services billed

1,031

199 women, 205 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 61%
Chronic kidney disease 60%
Arthritis 53%
Ischemic heart disease 52%
Heart failure 47%
Atrial fibrillation 36%
COPD 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

244 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record